Publications by authors named "S J Lupton"
Tissue histology and depuration of per- and polyfluoroalkyl substances (PFAS) from dairy cattle with lifetime exposures to PFAS-contaminated drinking water and feed.
Food Addit Contam Part A Chem Anal Control Expo Risk Assess
January 2025
Plasma, milk and tissue samples were collected from 30 dairy cattle (0.4 to 8.9 years of age) with lifetime exposures to perfluoroalkyl substances (PFAS) removed from a PFAS-contaminated farm and provided PFAS-free feed and water.
View Article and Find Full Text PDFDietary exposure levels to polychlorinated dibenzo--dioxins, polychlorinated dibenzofurans and non--polychlorinated biphenyls in US meat, poultry and siluriform fish from 2018 to 2019.
Food Addit Contam Part A Chem Anal Control Expo Risk Assess
March 2024
Daily dietary exposure estimates from beef, pork, chicken, turkey and siluriform fish were calculated using toxic equivalency (TEQ) data from the U.S. Department of Agriculture's survey of dioxins and dioxin-like compounds (DLCs) in the domestic meat supply and consumption data.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzed plasma and ear notch samples from 164 Holstein cows and heifers exposed to PFAS through contaminated feed and water, measuring nine specific PFAS using advanced mass spectrometry.* -
- PFCA compounds did not accumulate in plasma or skin, whereas longer-chain PFSAs did accumulate in both, requiring at least a year of exposure to stabilize in plasma.* -
- Lactation status significantly influenced PFSA levels in ear notch samples, while parity and lactation status had no effect on mature cow plasma PFSA concentrations, suggesting skin samples could be an alternative for biomonitoring.*
Hexabromocyclododecane (HBCD) is a brominated flame retardant (BFR) labeled by the Stockholm Convention as a persistent organic pollutant (POP) and exists primarily as three stereoisomers, i.e. α-, β-, and γ.
View Article and Find Full Text PDFArticle Synopsis
- Anti-drug antibodies linked to treatment failure in inflammatory bowel disease (IBD) patients on anti-TNF agents were analyzed in a large UK study involving 1058 participants.
- The study found that patients who developed antibodies to their first anti-TNF drug were more likely to also develop antibodies to their second anti-TNF drug, indicating a potential pattern of immunogenicity across different treatments.
- Introducing an immunomodulator when switching anti-TNF therapies boosted treatment persistence in patients with immunogenicity, suggesting that combined therapies may enhance outcomes in IBD management.